Celltrion secures $730 mn to buy biosimilar unit shares, pursue M&A
Celltrion Holdings Co. has secured 1 trillion won ($732 million) in fresh funding and plans to spend half of it this year to buy shares in its biosi...
Growth equity portfolio largely shielded from policy headwinds: Summit
Growth equity investments have remained largely stable in the face of recent policy shifts, with key sectors like technology and healthcare avoiding...
Affirma Capital to acquire Equis’ Korean waste assets for $294 million
Affirma Capital, a Singapore-headquartered buyout private equity firm, has agreed to acquire the entire portfolio of South Korean waste processing a...
Celltrion shares rise after bonus issue announcement
Celltrion Inc., South Korea’s largest biosimilar developer, will issue bonus shares to bolster its stock performance, which has been in the do...
Samsung Biologics to spin off biosimilar unit Samsung Bioepis
Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufac...
KIC bets on Asian real estate; eyes residential, data centers
The Korea Investment Corporation (KIC) is zeroing in on Asia’s real estate market by region, while targeting residential facilities and data c...
NPS boosts allocation to direct lending, secondaries
The National Pension Service (NPS), the world’s third-largest pension fund, has been further diversifying its portfolio through increased expo...
Greystar hires ex-Samsung SRA manager to launch Seoul office
Greystar Real Estate Partners, the largest housing investment firm in the US, has hired Kang Junghwan, former managing director and head of portfoli...
SK Group seeks to sell SK Signet as part of sweeping portfolio realignment
South Korea’s second-largest conglomerate SK Group is seeking to divest SK Signet Inc., four years after acquiring the EV charger manufacturin...
Harman acquires Masimo’s audio arm in Samsung’s car audio push
Harman International Industries Inc., wholly owned by Samsung Electronics Co., has acquired Masimo Corp.’s audio business for $350 million, a ...
Korea’s pharmaceutical exports set to top $10 bn, led by ‘K-M7’ champions
South Korea’s pharmaceutical exports are on course to surpass $10 billion this year, underscoring the country’s growing clout in the glo...
Celltrion expands footprint in Latin America with flagship oncology drugs
South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US
South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...
BlackRock sees digital assets at critical turning point
Digital assets are poised for robust structural growth – not just as investment vehicles but as strategic assets – fueled by growing ins...
S.Korea’s NPS to double pension fund size by 2050, hike risky assets
South Korea’s National Pension Service (NPS) is projected to nearly double its fund size to 3,500 trillion won ($2.38 trillion) by 2050, follo...
LG Energy, Doosan Bobcat tie up for construction equipment battery packs
LG Energy Solution Ltd., the world’s third-largest battery maker, and Doosan Bobcat Inc., a global construction machinery producer, said on We...
S.Korea’s pension fund NPS to overhaul alternative investment strategy
The National Pension Service (NPS), South Korea’s state-run pension fund and the country’s largest institutional investor, plans to intr...
Samsung, Celltrion lead biosimilar market in Europe, US
Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
Korean court rules in favor of Samsung Bioepis over Regeneron’s Eylea
A South Korean court on Friday ruled in favor of Samsung Bioepis Co. in a patent dispute against Regeneron Pharmaceuticals Inc., a US pharmaceutical...
SK Ecoplant seeks to sell waste treatment business for $1.4 billion
SK Ecoplant Co., a South Korean construction engineering and waste management company under SK Group, is seeking to dispose of its waste treatment b...
LX International seeks to acquire nickel, copper mines in Indonesia
LX International Corp., the trading unit of South Korea’s LX Group, said on Friday it is seeking to acquire a nickel mine and a copper mine in...
Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe
South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...
Korean drugmakers control more than half of European biosimilar market
South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...
Celltrion obtains approval of Steqeyma from FDA
South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...
Celltrion’s 4 new biosimilars win EU approval recommendation
Celltrion Inc. is one step closer to commercializing its four new biosimilars in Europe after a committee of the European Medicines Agency (EMA) rec...
Celltrion gets approval of Omlyclo in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...
SK promotes restructuring keymen to SK On, SK Discovery top posts
SK Group on Thursday promoted the keymen of its business overhauls to top posts at intermediary holding company SK Discovery Co. and battery maker S...
Celltrion to break ground on CDMO plant in 2025: Chairman Seo
South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...
